Efficacy of monotherapies and artesunate-based combination therapies in children with uncomplicated malaria in Somalia

Acta Tropica

Volumn 109, Issue 2, 2009, Pages 146-151

  Warsame, Marian ^a,b   Atta, Hoda ^b   Klena, John D ^c   Waqar, Butt Ahmed ^b   Elmi, Hussein Haji ^b   Jibril, Ali Mohamed ^d   Hassan, Hassan Mohamed ^e   Hassan, Abdullahi Mohamed ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c US Naval Medical Research Unit No 3 Egypt   (Egypt)

^d INTERSOS   (Somalia)

^e WHO Somalia ^*  (Somalia)

Author keywords

Amodiaquine; Artemisinin based combination therapy; Artesunate; Chloroquine; Efficacy; Somalia; Sulfadoxine pyrimethamine

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTESUNATE; CHLOROQUINE; FANSIDAR;

CHILD CARE; CHILD HEALTH; DISEASE TREATMENT; DRUG; HEALTH POLICY; MALARIA;

ARTICLE; BLOOD SAMPLING; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GROUPS BY AGE; HEALTH CARE POLICY; MALARIA; MALARIA CONTROL; MONOTHERAPY; SOMALIA; TREATMENT FAILURE; TREATMENT OUTCOME;

AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; MALARIA; MALE; PYRIMETHAMINE; SOMALIA; SULFADOXINE; TREATMENT OUTCOME;

AFRICA; EAST AFRICA; SOMALIA; SUB-SAHARAN AFRICA;

ARTESUNATE;

EID: 58049209665     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2008.10.009     Document Type: Article

References (32)

1. Bonnet M., Roper C., Felix M., Coulibaly L., Kankolongo G.M., and Guthmann J.P. Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zerekore. Malar. J. 6 (2007) 54
2. Bosman A., and Mendis K.N. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am. J. Trop. Med. Hyg. 77 (2007) 193-197
3. Cattamanchi A., Kyabayinze D., Hubbard A., Rosenthal, and Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am. J. Trop. Med. Hyg. 68 (2003) 133-139
4. Dorsey G., Staedke S., Clark T.D., Njama-Meya D., Nzarubara B., Maiteki-Sebuguzi C., Dokomajilar C., Kamya M.R., and Rosenthal P.J. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 297 (2007) 2210-2219
5. Faye B., Ndiaye J.L., Ndiaye D., Dieng Y., Faye O., and Gaye O. Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malar. J. 6 (2007) 80
6. Govere J.M., La Grange J.J., Durrheim D.N., Freese J.A., Sharp B.L., Mabuza A., Mngomezulu N., and Bredenkamp B.L. Sulfadoxine-pyrimethamine effectiveness against Plasmodium falciparum malaria in Mpumalanga Province, South Africa. Trans. R. Soc. Trop. Med. Hyg. 93 (1999) 644
7. Ibrahium A.M., Kheir M.M., Osman M.E., Khalil I.F., Alifrangis M., Elmardi K.A., Malik E.M., and Adam I. Efficacies of artesunate plus either sulfadoxine-pyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. Ann. Trop. Med. Parasitol. 101 (2007) 15-21
8. Mockenhaupt F.P., Ehrhardt S., Dzisi S.Y., Teun Bousema J., Wassilew N., Schreiber J., Anemana S.D., Cramer J.P., Otchwemah R.N., Sauerwein R.W., Eggelte T.A., and Bienzle U. A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Trop. Med. Int. Health 10 (2005) 512-520
9. Mubyazi G.M., and Gonzalez-Block M.A. Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug. Malar. J. 4 (2005) 51
10. Mugittu K., Adjuik M., Snounou G., Ntoumi F., Taylor W., Mshinda H., Olliaro P., and Beck H.P. Molecular genotyping to distinguish between recrudescents and new infections in treatment trials of Plasmodium falciparum malaria conducted in Sub-Saharan Africa: adjustment of parasitological outcomes and assessment of genotyping effectiveness. Trop. Med. Int. Health 11 (2006) 1350-1359
11. Mårtensson A., Strömberg J., Sisowath C., Msellem M.I., Gil J.P., Montgomery S.M., Olliaro P., Ali A.S., and Björkman A. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar Tanzania. Clin. Infect. Dis. 41 (2005) 1079-1086
12. Nosten F., Van Vugt M., Price R., Luxemburger C., Thway K.L., Brockman A., Mcgready R., Ter Kuile F., Looareesuwan S., and White N.J. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356 (2000) 297-302
13. Nsimba B., Malonga D.A., Mouata A.M., Louya F., Kiori J., Malanda M., Yocka D., Oko-Ossho J., Ebata-Mongo S., and Le Bras J. Efficacy of sulfadoxine/pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in Republic of Congo. Am. J. Trop. Med. Hyg. 70 (2004) 133-138
14. Obonyo C.O., Ochieng F., Taylor W.R., Ochola S.A., Mugitu K., Olliaro P., Ter Kuile F., and Oloo A.J. Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial. Trans. R. Soc. Trop. Med. Hyg. 97 (2003) 585-591
15. Price R.N., Nosten F., Luxemburger C., Ter Kuile F.O., Paiphun L., Chongsuphajaisiddhi T., and White N.J. Effects of artemisinin derivatives on malaria transmissibility. Lancet 347 (1996) 1654-1658
16. Priotto G., Kabakyenga J., Pinoges L., Ruiz A., Eriksson T., Coussement F., Ngambe T., Taylor W.R., Perea W., Guthmann J.P., Olliaro P., and Legros D. Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda: a randomized, double-blind, placebo-controlled trial. Trans. R. Soc. Trop. Med. Hyg. 97 (2003) 325-330
17. Rogier C., Pradines B., Bogreau H., Koeck J.-L., Kamil M.A., and Mercereau-Puijalon O. Malaria epidemic and drug resistance Djibouti. Emerg. Infect. Dis. 11 (2005) 317-321
18. Shretta R., Omumbo J., Rapuoda B., and Snow R.W. Using evidence to change antimalarial drug policy in Kenya. Trop. Med. Int. Health 5 (2000) 755-764
19. Sowunmi A., Fehintola F.A., Adedeji A.A., Gbotosho G.O., Tambo E., Fateye B.A., Happi T.C., and Oduola A.M. Open randomized study of artesunate-amodiaquine vs. chloroquine-pyrimethamine-sulfadoxine for the treatment of uncomplicated Plasmodium falciparum malaria in Nigerian children. Trop. Med. Int. Health 10 (2005) 1161-1170
20. Tinto H., Zoungrana E.B., Coulibaly S.O., Ouedraogo J.B., Traore M., Guiguemde T.R., Van Marck E., and D'alessandro U. Chloroquine and sulphadoxine-pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo-Dioulasso, Burkina Faso during a 3-year period 1998-2000. Trop. Med. Int. Health 7 (2002) 925-930
21. Viriyakosol S., Siripoon N., Petcharapirat C., Petcharapirat P., Jarra W., Thaithong S., Brown N.K., and Snounou G. Genotyping of Plasmodium falciparum isolates by the polymerase chain reaction and potential uses in epidemiological studies. Bull. World Health Org. 73 (1995) 85-95
22. Von Seidlein L., Milligan P., Pinder M., Bojang K., Anyalebechi C., Gosling R., Coleman R., Ude J.I., Sadiq A., Duraisingh M., Warhurst D., Alloueche A., Targett G., Mcadam K., Greenwood B., Walraven G., Olliaro P., and Doherty T. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet 355 (2000) 352-357
23. Warsame M., Perlmann H., Ali S., Hagi H., Farah S., Lebbad M., and Bjorkman A. The seroreactivity against Pf155 (RESA) antigen in villagers from a mesoendemic area in Somalia. Trop. Med. Parasitol. 40 (1989) 412-414
24. Warsame M., Wernsdorfer W.H., Willcox M., Kulane A.A., and Bjorkman A. The changing pattern of Plasmodium falciparum susceptibility to chloroquine but not to mefloquine in a mesoendemic area of Somalia. Trans. R. Soc. Trop. Med. Hyg. 85 (1991) 200-203
25. Warsame M., Abdillahi A., Duale O.N., Ismail A.N., Hassan A.M., Mohamed A., and Warsame A. Therapeutic efficacy of chloroquine and sulfadoxine/pyrimethamine against Plasmodium falciparum infection in Somalia. Bull. World Health Organ. 80 (2002) 704-708
26. White N.J. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob. Agents Chemother. 41 (1997) 1413-1422
27. White N.J., and Olliaro P.L. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol. Today 12 (1996) 399-401
28. WHO, 2001. Antimalarial drug combination therapy: report of a WHO technical consultation. World Health Organization, Geneva. WHO/CDS/RBM/2001.35.
29. WHO, 2003. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. WHO/HTM/RBM/2003.50.
30. WHO, 2005. Susceptibility of Plasmodium falciparum to antimalarial drugs: report on global monitoring, 1996-2004. WHO/HTM/MAL/2005.1103.
31. WHO/UNICEF, 2005. World Malaria Report. World Health Organization, Geneva. http://www.rollbackmalaria.org/wmr2005/.
32. WHO, 2008. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. World Health Organization, Geneva. http://www.who.int/malaria/docs/drugresistance/MalariaGenotyping.pdf.